子宫癌肉瘤23例临床分析  

Analysis the clinical features of Uterine Mixed Mullerian Tumor in 23 cases

作　　者：王淑琴[1] 程继荣[1] 齐玲[2] 

机构地区：[1]新疆医科大学第五附属医院肿瘤综合病房,新疆乌鲁木齐830011 [2]新疆医科大学第五附属医院妇科,新疆乌鲁木齐830011

出　　处：《新疆医科大学学报》2009年第1期39-41,共3页Journal of Xinjiang Medical University

摘　　要：目的:研究子宫癌肉瘤临床数据,探讨更好的诊断及治疗。方法:对子宫肉瘤患者23例进行回顾性分析,其中宫体癌肉瘤15例,宫颈癌肉瘤8例。手术:17例,术后化疗8例,化疗+放疗3例。结果:本组Ⅰ和Ⅱ期患者18例,2、5年生存率分别为74.5%和59.2%;Ⅲ和Ⅳ期仅5例,2、5年生存率分别为16.7%和0%。结论:诊断性刮宫对子宫内膜间质肉瘤、癌肉瘤及恶性中胚叶混合瘤的诊断价值较大;早期病例采用术后辅助放化疗的综合治疗可能对延长生存期,减少复发和远处转移有一定帮助。Objective： To study the clinical data of uterine Mullerian Tumor in 23 cases and try to find the better way to improve overall survival as well as diagnosis and treatment. Methods： Twenty three cases with uterine sarcoma were analyzed retrospectively, among which there were 15 cases with leiomyosarcoma, 8 with malignant mesodermal mixed tumor. Results： Seventeen cases underwent surgory alone; Eight surgery plus postoperative chemotherapy and three chemotherapy plus irradiation. The 2 and 5 year survival rate for stage Ⅰ and Ⅱwas 74.5% and 59.2 raspectively. The 2 and 5 year survival rate for stage Ⅲ and Ⅳ as 16.70% and 0% raspectively. Conclusions： The prognosis of uterine MMT is closely related to clinical stage, histologic type. Diagnostic curet tage is useful for endomet rialstromal sarcoma, earcinosarcoma, and malignant mesodermal mixed tumor. The mainstay of the treatment is surgery postoperative chemotherapy can decreased recurrent and metastatic cases.

关 键 词：子宫肉瘤 手术后化疗 组织学类型 预后 

分 类 号：R737.33[医药卫生—肿瘤]